CLINICAL STUDY
Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction
Philippe Menasché, MD, PhD*,*,
Albert A. Hagège, MD, PhD ,
Jean-Thomas Vilquin, PhD ,
Michel Desnos, MD,
Eric Abergel, MD,
Bruno Pouzet, MD*,
Alain Bel, MD*,
Sorin Sarateanu, MD*,
Marcio Scorsin, MD, PhD*,
Ketty Schwartz, PhD,
Patrick Bruneval, MD ,
Marc Benbunan, MD||,
Jean-Pierre Marolleau, MD|| and
Denis Duboc, MD¶
* Assistance Publique-Hôpitaux de Paris, Department of Cardiovascular Surgery B, Hôpital Bichat, Paris, France
Department of Cardiology, Hôpital Européen Georges Pompidou and INSERM EMI 00-16, Faculté de Médecine Necker Enfants-Malades, Paris V University, Paris, France
INSERM U 582, Groupe Hospitalier Pitié Salpêtrière, Paris, France
Department of Pathology, Hôpital Européen Georges Pompidou, Paris, France
|| Laboratory of Cell Therapy, Hôpital Saint Louis, Paris, France
¶ Department of Cardiology, Hôpital Cochin, Paris V University, Paris, and Department of Nuclear Medicine Frédéric Joliot, Commissariat à l’Energie Atomique, Orsay, France
Manuscript received June 11, 2002;
revised manuscript received October 2, 2002,
accepted October 17, 2002.
* Reprint requests and correspondence: Dr. Philippe Menasché, Département de Chirurgie Cardiovasculaire, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France.
philippe.menasche{at}hop.egp.ap-hop-paris.fr
 |
Abstract
|
|---|
OBJECTIVES: This phase I trial was designed to assess the feasibility and safety of autologous skeletal myoblast transplantation in patients with severe ischemic cardiomyopathy.
BACKGROUND: Experimentally, myoblast grafting into postinfarction myocardial scars improves left ventricular function.
METHODS: Ten patients were included on the basis of the following criteria: 1) severe left ventricular dysfunction (ejection fraction  35%); 2) the presence of a postinfarction akinetic and nonviable scar, as assessed by dobutamine echocardiography and 18-fluorodeoxyglucose positron emission tomography; and 3) an indication of coronary bypass in remote areas. Skeletal myoblasts were grown from a biopsy taken at the thigh.
RESULTS: An average of 871 x 106 cells (86% of myoblasts) were obtained after a mean period of 16 days and implanted uneventfully across the scar at the time of bypass. Except for one patient whose early death was unrelated to the cell transplantation, all patients had an uncomplicated postoperative course. Four patients showed delayed episodes of sustained ventricular tachycardia and were implanted with an internal defibrillator. At an average follow-up of 10.9 months, the mean New York Heart Association functional class improved from 2.7 ± 0.2 preoperatively to 1.6 ± 0.1 postoperatively (p < 0.0001), and the ejection fraction increased from 24 ± 1% to 32 ± 1% (p < 0.02). A blinded echocardiographic analysis showed that 63% of the cell-implanted scars (14 of 22) demonstrated improved systolic thickening. One noncardiac death occurred 17.5 months after transplantation.
CONCLUSIONS: These preliminary data suggest the feasibility and safety of autologous skeletal myoblast transplantation in severe ischemic cardiomyopathy, with the caveat of an arrhythmogenic potential. New-onset contraction of akinetic and nonviable segments suggests a functional efficacy that requires confirmation by randomized studies.
|
Abbreviations and Acronyms
| | AICD | = automatic internal cardioverter-defibrillator | | CABG | = coronary artery bypass graft | | 18FDG | = fluorine-18–labeled fluorodeoxyglucose | | LV | = left ventricle/ventricular | | LVEDV | = left ventricular end-diastolic volume | | LVEF | = left ventricular ejection fraction | | LVESV | = left ventricular end-systolic volume | | NYHA | = New York Heart Association | | PET | = positron emission tomography | | VT | = ventricular tachycardia |
|
Heart failure is a major and expanding public health concern; in most cases, it results from myocardial infarction, leading to an akinetic fibrous scar and associated left ventricular (LV) remodeling. Despite dramatic improvements in the medico-surgical management of these patients, their persistently dismal outlook (1) still justifies the ongoing search for new treatments.
In this setting, cellular transplantation is receiving a growing interest as a means of replacing lost cardiomyocytes by exogenously supplied contractile cells, among which the skeletal myoblasts, which are responsible for skeletal muscle formation and repair, feature clinically attractive characteristics, including ease of procurement, growth potential in vitro, and strong resistance to ischemia.
Experimentally, engrafted skeletal myoblasts differentiate into myotubes and improve postinfarction cardiac function (2–8). These observations have set the stage for this phase I human trial in which the first patient was operated on June 15, 2000 (9).
|
Methods
|
|---|
Inclusion criteria.
Eligibility for inclusion was based on: 1) systolic LV dysfunction, as reflected by an echocardiographic LV ejection fraction (LVEF) 35%; 2) a history of myocardial infarction with a residual akinetic and nonviable scar, as demonstrated by a lack of response to low-dose dobutamine echocardiography and of metabolic activity on fluorine-18 fluorodeoxyglucose (18FDG) positron emission tomography (PET); and 3) an indication for concomitant coronary artery bypass graft (CABG) in remote (i.e., different from the transplanted area) and viable but ischemic myocardium. The main exclusion criteria consisted of diabetes, cardiogenic shock, unstable angina requiring urgent surgery, peripheral muscular dystrophy, and positive serologic test results for human immunodeficient virus and hepatitis.
This protocol was approved by the French Regulatory Health Authorities and our ethics committee. Patients were included after having received extensive information and giving their witnessed consent.
Preoperative screening.
Transthoracic two-dimensional echocardiography was performed using fundamental and second-harmonic imaging. Global LVEF (%) was calculated from measurements of LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV; both in ml) using the biplane Simpson’s rule, as  (10). Regional contractile function was assessed semiquantitatively after division of the LV into 16 segments, as recommended by the American Society of Echocardiography (10). Care was taken to optimize endocardial visualization on three parasternal short-axis views of the LV (at the base, mid-ventricular level, and apex) and apical two-, three-, and four-chamber views. Segmental thickening of each segment was then visually evaluated and graded as dyskinetic, akinetic, severely hypokinetic, moderately hypokinetic, or normal (11). This initial assessment was performed within the month before surgery, not during episodes of cardiac failure, and at rest; and dobutamine (5, 10, and 15 µg/kg per min without exceeding a 10-beats/min increase in heart rate) was used to check for the absence of induced segmental thickening in the infarcted area (12,13).
The 18FDG PET studies were performed with a whole-body scanner (ECAT Exact, CTI/Siemens, Knoxville, Tennessee) with an intrinsic spatial resolution of 6 mm full width at half maximum. To augment myocardial glucose uptake, each patient received 50 g of glucose orally. One hour later, 18FDG (370 MBq) was injected intravenously and six images of 5 min each were acquired after 13 min. The relative regional myocardial 18FDG uptake was determined on three short-axis slices that corresponded in location to the echocardiographic sections and to the surgical map depicting the sites of cell injections. Regional myocardial 18FDG activity concentrations were defined as the ratio over the maximum myocardial 18FDG uptake. Segments with 50% 18FDG uptake were defined as nonviable (14).
Staging of the procedure.
Muscular biopsy
A 10- to 15-g piece of the vastus lateralis muscle was retrieved from the patient’s thigh under local anesthesia, minced, and transported in a preservation medium to the Cell Therapy Laboratory.
Cell cultures
The general methodology has been previously described (9). Briefly, the muscle biopsy was digested using collagenase and trypsin. The primary cell culture was expanded in cell factories using a clinical grade myogenic-specific medium based on a modification of MCDB120, supplemented with bovine fetal serum, basic fibroblast growth factor, dexamethasone, penicillin, and streptomycin. The cells were expanded and harvested before reaching confluency by trypsinization. Scale-up was performed to achieve the following targets: at least 500 x 106 cells,  50% myoblasts, and 70% viable cells. Finally, cells were collected by trypsinization, washed, and suspended in albumin (150 x 106 cells/ml). Quality control was performed throughout the process and for the final product. The percentage of myoblasts and viable cells was quantified by flow cytofluorimetry after staining for CD56, a marker specific for skeletal muscle cells, and upon exclusion of propidium iodide, respectively. Preclinical double-labeling fluorocytometric analyses have demonstrated that most CD56-positive cells were also positive for desmin. Short- and long-term microbiologic control studies were performed repeatedly. The cell-containing suspension was transferred into sterile syringes, which were shipped back at room temperature to the cardiac surgery department. One aliquot of the final product was retained for testing the myogenic capacity of the cells, and, in the first five patients, another aliquot was used for tumorigenic testing by injecting 5 x 105 cells intravenously into irradiated nonobese diabetic-severe combined immunodeficient mice.
Cell transplantation
Under cardioplegic arrest, the cell suspension was injected within and around the scar, using a customized prebent 27-gauge needle, allowing tangential injections and thus reducing the risk of intracavitary cell delivery.
There was no specific postoperative treatment except for corticosteroids (prednisolone, 780 mg), given over the first two postoperative days.
Assessment of outcomes.
The primary end points were feasibility and safety. Feasibility was defined as the ability of the expansion procedure to yield the target numbers of cells within two to three weeks. Safety referred to adverse events related to biopsy/cell reimplantation and specifically involved detection of ventricular arrhythmias by 24-h Holter electrocardiographic (ECG) monitoring studies performed before and within the first three postoperative months.
The secondary end point was efficacy, which was primarily assessed by two-dimensional echocardiographic analysis of LV function at one, three, and six months postoperatively and at the end of follow-up. In addition to measurements of global LVEF, serial changes in LV segmental thickening were evaluated semiquantitatively and classified as unchanged, improved (1 grade), or worsened (1 grade). These grafted areas were localized by reference to the intraoperative diagram depicting the injection sites. Image analysis was performed by two investigators, one of whom was blinded to the timing of echocardiography, the number and location of coronary bypasses, and the sites of cell injections.
Statistics.
Results are reported as the mean value ± SEM. A comparison of preoperative and postoperative data was done using the paired t test, with p < 0.05 as the limit of significance.
|
Results
|
|---|
Study group.
The study group (Table 1) comprised 10 male patients with a mean age of 60 ± 3 years (range 38 to 73). The age of the infarct was 6.2 ± 1.9 years (range 1 month to 19 years), and its location was anterior (n = 6), posterior (n = 3), or posterolateral (n = 1). All of the infarcted areas were angiographically subserved by totally occluded, nonrevascularizable coronary arteries.
All patients had evidence of myocardial ischemia, as demonstrated by angina or stress tests, and/or clinical symptoms of congestive heart failure. Four patients were in New York Heart Association (NYHA) functional class II; five in class III; and one in class IV. The LVEF was 24.3 ± 1.3% (range 18% to 34%), and the 18FDG uptake ratio was 0.41 ± 0.04.
Cell cultures.
Histologic analysis of the biopsied muscle revealed normal anatomy. The target numbers of cells were consistently achieved in all patients within two to three weeks (i.e., 953 ± 71 x 106 cells [range 530 to 1,215] were produced in 16 ± 1 days [range 14 to 20]). All cultures contained more than 60% myogenic cells (mean 86 ± 3% [range 67% to 97%]) and more than 90% viable cells (mean 95 ± 1% [range 86% to 99%]). There was no bacterial or fungal contamination. None of the NOD-SCID mice injected with myoblasts developed a macroscopically detectable tumor. Myoblasts that were replated at the time of final cell collection grew to confluency and then differentiated and fused to form multinucleated myotubes characteristic of skeletal muscle tissue.
Cell transplantation.
All patients had two bypass grafts except for one patient who had three. An average volume of 5.7 ± 0.3 ml (range 4 to 8) containing 871 ± 62 x 106 (range 500 to 1,115) was injected in 37 ± 3 sites (range 27 to 57) throughout the scar area (29 ± 3 cm2 [range 20 to 40]). The procedure averaged 18 ± 1 min (range 15 to 26) and was consistently uneventful.
Early postoperative course.
There was no complication related to the muscular biopsy. One patient (no. 5) in NYHA class IV with a history of three previous infarctions died early after the operation, likely due to a mesenteric infarction subsequent to a profound hemodynamic deterioration, which occurred suddenly before cardiopulmonary bypass was instituted. The postoperative course of the other nine patients was uneventful.
Short-term outcomes.
By April 1, 2002, the follow-up period averaged 10.9 ± 4.5 months (range 5 to 17.5).
The only adverse event likely related to the procedure was the occurrence of sustained, monomorphic ventricular tachycardia (VT) featuring a right conduction delay pattern in four patients, three of whom had preoperative ventricular hyperexcitability (grade 2 to 3 in Lown’s classification). All these VTs occurred early after the operation (11 to 22 days) and, except for one syncopal form, were clinically well tolerated. None of these arrhythmias occurred in the setting of myocardial ischemia, which was consistently ruled out by the absence of suggestive clinical and ECG changes and full angiographic patency of all grafts. The four patients were implanted with an automatic internal cardioverter-defibrillator (AICD), either shortly after the operation because of the inducibility of VT on programmed ventricular stimulation (n = 2; Patient nos. 7 and 8) or later (Patient nos. 4 and 6) because of a delayed recurrence of VT (at five and nine months postoperatively), despite antiarrhythmic drug therapy (beta-blockers and amiodarone). Among the two patients who had late device implantation, only one had undergone an early postoperative stimulation, which failed to induce VT. At follow-up after AICD implantation (one month in one case and eight months in the other three cases), only one of the four device-implanted patients had experienced two appropriate shocks. In the last three patients in the trial, amiodarone therapy was prophylactically instituted at the time of biopsy and continued for three months. One patient still experienced asymptomatic VT (he is one of those who received an early postoperative defibrillator), but at the time of the latest follow-up visit, the two others had remained arrhythmia-free. The small size of the sample did not allow us to conclusively establish a correlation between the number of injected cells and the occurrence of VT.
Efficacy data pertain to eight of the nine operative survivors, as the poor echogenicity of Patient no. 7 led to his exclusion from further segmental analysis by the blinded observer. For these eight patients, there was complete agreement between the two observers regarding the postoperative improvement in systolic thickening 1 grade. In this cohort, LVEF rose from 23.8 ± 3.9% (range 18% to 31%) preoperatively to 32.1 ± 7.5% (range 25% to 45%) postoperatively (p < 0.02), whereas LVEDV remained statistically unchanged (124 ± 46 ml/m2 [range 56 to 154] postoperatively vs. 107 ± 31 ml/m2 [range 69 to 198] preoperatively). According to the surgical map, 22 in-scar segments were implanted with cells. Postoperatively, 14 of them (63%) demonstrated new-onset echocardiographic systolic shortening (6 of 8 patients), with the number of improved segments increasing over time (from 8 before 3 months to 14 at the end of follow-up). In comparison, 26 noninjected but revascularized segments improved echocardiographically to a similar extent as the grafted ones after the procedure. This amelioration translated into an improvement in NYHA class from 2.7 ± 0.2 to 1.6 ± 0.1 (p < 0.0001), whereas preoperative medications were continued unchanged after surgery, except for diuretics, the dose of which was tailored to the magnitude of congestive symptoms. Only one patient required a brief rehospitalization for a transient episode of heart failure related to inadvertent discontinuation of diuretics. One patient (Patient no. 1) died of a stroke at 17.5 months postoperatively. The improvement of his cardiac function (both global and segmental), which was manifest early postoperatively, was sustained thereafter until the time of his death. Autopsy found clusters of myotubes embedded in the scar tissue, without evidence of cardiomyogenic differentiation, as reflected by the lack of gap junction formation.
|
Discussion
|
|---|
Feasibility.
Our first objective was to assess whether cell culture procedures routinely used experimentally could be clinically upgraded so as to make them compatible with human use. From this standpoint, the present results are satisfactory, as a large number of cells could reproducibly be grown from the initial muscle biopsy within two to three weeks and in strict compliance with Good Manufacturing Practice constraints. Because the functional outcome following myoblast transplantation is related to the number of injected cells (15), the lower target cell yield was set at 500 x 106, at least 50% of which were required to be myoblasts. Our data show that these thresholds were consistently overshot. Although it is technically possible to grow more than one billion cells, such numbers would require larger injection volumes, which raises a potential safety issue. Reducing this volume by increasing the cell concentration would, in turn, expose the cells to damage subsequent to their passage through a necessarily small-bore needle.
Cultures were obtained expeditiously in all patients, regardless of their age and comorbidities. Likewise, there was little variability in the percentage of myogenic cells or their functional capacity to form multinucleated myotubes in vitro.
Safety.
There were no perioperative complications related to biopsy or cell injections. The two early and late deaths were clearly unrelated to the cell transplantation procedure.
The absence of tumor in myoblast-injected immunodeficient mice confirms that oncogenicity is unlikely to be a concern with autologous transplantation of primarily cultured skeletal myoblasts. When these myoblasts were exposed to the differentiation medium, they never turned to cells of a different nature (i.e., osteoblasts, chondroblasts). This commitment to a strictly myogenic lineage is due to the already advanced stage of differentiation of myoblasts and contrasts with the greater phenotypic plasticity of bone marrow stem cells, which are also considered for intramyocardial grafting.
The only serious adverse event likely related to the procedure was the occurrence of ventricular arrhythmias in four patients, although such a relationship may be confounded by the trend for patients with ischemic cardiomyopathies to develop arrhythmic events (16). Skeletal myoblasts and cardiomyocytes express different sets of ion channels (17) whose distinct kinetic activation/inactivation patterns could result in arrhythmogenic inhomogeneities in action potential conduction. In fact, inhomogeneous intramyocardial distribution of gap junctions increases the risk of arrhythmias (18). Alternatively, these arrhythmias could have an inflammatory origin due to both needle punctures and early cell death from necrosis and/or apoptosis, as shown in other models of cell transplantation (19,20). These events would then trigger the release of inflammatory cell-derived arrhythmogenic products, as occurs during myocarditis (21). Finally, reentry pathways could be created by cell-independent, injection-related disorganization of the supracellular myocardial anatomy in the border zone. These various hypotheses are currently under experimental investigation.
In the four patients who experienced VT, the decision to implant a defibrillator was based on standard transplantation-independent criteria and is consistent with the survival benefit expected from the device in this patient population at high risk of severe arrhythmic events, as shown by the recently reported Multicenter Automatic Defibrillator Implantation Trial (MADIT) II trial (22).
Efficacy.
This phase I trial was neither designed nor powered to assess the efficacy of the procedure, so only careful and preliminary conclusions can be drawn from the comparison of postoperative versus preoperative data.
As improvement in symptoms and LVEF may simply reflect efficacious revascularization, analysis of echocardiograms primarily focused on contractile changes of the cell-transplanted scarred segments. Fourteen of 22 of these segments had improved kinetics, as evidenced by new-onset systolic thickening. Experimentally, myoblast transplantation limits postinfarction ventricular dilation (23), but this mechanism was probably not operative in our patients with old infarctions and already enlarged ventricular dimensions that did not regress postoperatively. Echocardiographic data rather suggest a contribution of engrafted myotubes to contractile function. As these cells do not express connexin 43–supported gap junctions with host cardiomyocytes (24), classic electromechanical coupling is unlikely. However, skeletal myoblasts could respond mechanically to the contraction of surrounding host cardiomyocytes to which they may be bound through the extracellular matrix (25). Alternatively, engrafted myoblasts may release growth factors, particularly insulin-like growth factor-1, with a subsequent paracrine recruitment of cardiac stem cells (26) that would promote a new endogenous pool of contractile cells.
Study limitations.
A first limitation pertains to the semiquantitative approach used for assessing segmental function. Although two-dimensional echocardiography has become the technique of choice for direct visualization of endocardial motion and wall thickening (27), this assessment may still be confounded by contractile changes of the adjacent segments, as long as myocardial strain is not directly measured. The improved kinetics of the revascularized segments could therefore have skewed the grading of transplanted areas.
A second limitation is the possible confounding effect of concomitant CABG. Two lines of reasoning, however, temper this concern. First, 18FDG glucose uptake <50% relative to that of the area of maximal tracer uptake, which defines nonviable scar tissue (14,28), and the lack of contractile response to low-dose dobutamine are both predictable of functional recovery after revascularization, with a negative predictive power in the range of 90% (11,29–32). Thus, at most, 10% of the nonviable segments would have been expected to improve following bypass alone (29–31,33,34), which is in contrast to the observed improvement rate of 63% following transplantation. Second, pathologic studies have shown that nonviable myocardial areas are primarily made of fibrosis (35), with <25% still viable myocytes (36). Because at least 50% of a segment’s myocytes need to be functionally viable to improve following revascularization (36), it is conceivable that the contractile elements that accounted for new-onset systolic thickening of transplanted segments were derived from the grafted myoblasts.
However, the extent to which the improved inotropism of the transplanted segments contributed to the increase in global LVEF remains uncertain. A critical determinant of LVEF recovery is the number of segments with improved wall motion, and this number needs to encompass more than 20% of the LV for global function to improve (37). Combined with revascularization, cell transplantation might contribute to reach this threshold.
Conclusions.
These data show that autologous skeletal myoblast transplantation is a feasible and straightforward procedure. Randomized trials are now required to further characterize the risk/benefit ratio of this novel approach.
|
Acknowledgments
|
|---|
The authors acknowledge the invaluable technical expertise and commitment of Marie-Noëlle Lacassagne, Isabelle Robert, and Brigitte Ternaux from the Laboratory of Cell Therapy (Hôpital Saint Louis).
|
Footnotes
|
|---|
This work was supported by the Délégation à la Recherche Clinique de l’Assistance Publique-Hôpitaux de Paris, as well as by grants from the Association Française contre les Myopathies and the Institut National de la Santé et de la Recherche Médicale (35 4CS15F and 35 7783). The authors acknowledge the support of the Commissariat à l’Energie Atomique (Prof. A. Syrota, Orsay, France).
|
References
|
|---|
1. Berry C, Murdoch D, McMurray J. Economics of chronic heart failure. Eur J Heart Fail. 2001;3:283–291[Abstract/Free Full Text]
2. Chiu RCJ, Zibaitis A, Kao RL. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann Thorac Surg. 1995;60:12–18[Abstract/Free Full Text]
3. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest. 1996;98:2512–2523[Medline]
4. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4:929–933[CrossRef][Medline]
5. Scorsin M, Hagège AA, Vilquin J-T, et al. Comparison of the effects of fetal cardiomyocytes and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg. 2000;119:1169–1175[Abstract/Free Full Text]
6. Pouzet B, Ghostine S, Vilquin J-T, et al. Is skeletal myoblast transplantation clinically relevant in the era of angiotensin-converting enzyme inhibitors? Circulation. 2000;104(Suppl I):I223–I228
7. Rajnoch C, Chachques J-C, Berrebi A, Bruneval P, Benoit MO, Carpentier A. Cellular therapy reverses myocardial dysfunction. J Thorac Cardiovasc Surg. 2001;121:871–878[Abstract/Free Full Text]
8. Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation. 2001;103:1920–1927[Abstract/Free Full Text]
9. Menasché P, Hagège AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet. 2001;357:279–280[CrossRef][Medline]
10. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography by the American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367[Medline]
11. Arnese M, Cornel JH, Salustri A, et al. Prediction of improvement of regional left ventricular function after surgical revascularization: a comparison of low-dose dobutamine echocardiography with 201Tl single-photon emission computed tomography. Circulation. 1995;91:2748–2752[Abstract/Free Full Text]
12. Pierard LA, De Landsheere CM, Berthe C, Rigo P, Kulbertus HE. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol. 1990;15:1021–1031[Abstract]
13. Sklenar J, Ismail S, Villanueva FS, Goodman NC, Glasheen WP, Kaul S. Dobutamine echocardiography for determining the extent of myocardial salvage after reperfusion. Circulation. 1994;90:1502–1512[Abstract/Free Full Text]
14. Gerber BL, Ordoubadi FF, Wijns W, et al. Positron emission tomography using 18F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of 18F-fluoro-deoxyglucose positron emission tomography for the detection of myocardial viability. Eur Heart J. 2001;22:1691–1701[Abstract/Free Full Text]
15. Pouzet B, Vilquin JT, Hagège AA, et al. Factors affecting functional outcome after autologous skeletal myoblast transplantation. Ann Thorac Surg. 2001;71:844–851[Abstract/Free Full Text]
16. Bigger JT, Whang W, Rottman JN, et al. Mechanisms of death in the CABG PATCH trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation. 1999;99:1416–1421[Abstract/Free Full Text]
17. Goldin AL. Diversity of mammalian voltage-gated sodium channels. Ann NY Acad Sci. 1999;868:38–50[CrossRef][Medline]
18. Gutstein DE, Morley GE, Tamaddon H, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin 43. Circ Res. 2001;88:333–339[Abstract/Free Full Text]
19. Beauchamp JR, Pagel CN, Partridge TA. A dual-marker system for quantitative studies of myoblast transplantation in the mouse. Transplantation. 1997;63:1794–1797[CrossRef][Medline]
20. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol. 2001;33:907–921[CrossRef][Medline]
21. Klein RM, Vester EG, Brehm MU, et al. Inflammation of the myocardium as an arrhythmia trigger. Z Kardiol. 2000;89(Suppl 3):24–35
22. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883[Abstract/Free Full Text]
23. Ghostine S, Carrion C, Guarita Souza LC, et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation. 2002;106(Suppl I):I131–I136
24. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle: implications for infarct repair. J Cell Biol. 2000;149:731–740[Abstract/Free Full Text]
25. Miyagawa S, Sawa Y, Taketani S, et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation. 2002;105:2556–2561[Abstract/Free Full Text]
26. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med. 2002;346:5–15[Abstract/Free Full Text]
27. Lieberman AN, Weiss JL, Judgutt BI, et al. Two-dimensional echocardiography and infarct size: relationship of regional wall motion and thickening to the extent of myocardial infarction in the dog. Circulation. 1981;63:739–746[Free Full Text]
28. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30:1693–1700[Abstract]
29. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884–888[Abstract]
30. Baer FM, Voth E, Deutsch HJ, et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose C for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol. 1996;28:60–69[Abstract]
31. Pagano D, Townend JN, Littler WA, Horton R, Camici PG, Bonser RS. Coronary artery bypass surgery as treatment for ischemic heart failure: the predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J Thorac Cardiovasc Surg. 1998;115:791–799[Abstract/Free Full Text]
32. Pasquet A, Lauer MS, Williams MJ, Secknus MA, Lytle B, Marwick TH. Prediction of global left ventricular function after bypass surgery in patients with severe left ventricular dysfunction: impact of pre-operative myocardial function, perfusion and metabolism. Eur Heart J. 2000;21:125–136[Abstract/Free Full Text]
33. Wiggers H, Nielsen TT, Bottcher M, Egeblad H, Botker HE. Positron emission tomography and low-dose dobutamine echocardiography in the prediction of postrevascularization improvement in left ventricular function and exercice parameters. Am Heart J. 2000;140:928–936[CrossRef][Medline]
34. Haas F, Augustin N, Holper K, et al. Time course and extent of improvement of dysfunctioning myocardium in patients with coronary artery disease and severely depressed left ventricular function after revascularization: correlation with positron emission tomographic findings. J Am Coll Cardiol. 2000;36:1927–1934[Abstract/Free Full Text]
35. Maes A, Flameng W, Nuyts J, et al. Histological alterations in chronically hypoperfused myocardium: correlation with PET findings. Circulation. 1994;90:735–745[Abstract/Free Full Text]
36. Baumgartner H, Porenta G, Lau YK, et al. Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT: correlation with histopathology in explanted hearts. J Am Coll Cardiol. 1998;32:1701–1708[Abstract/Free Full Text]
37. Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995;92:3436–3444[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
N. Sekiya, G. Matsumiya, S. Miyagawa, A. Saito, T. Shimizu, T. Okano, N. Kawaguchi, N. Matsuura, and Y. Sawa
Layered implantation of myoblast sheets attenuates adverse cardiac remodeling of the infarcted heart.
J. Thorac. Cardiovasc. Surg.,
October 1, 2009;
138(4):
985 - 993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic
Cardiac Cell Repair Therapy: A Clinical Perspective
Mayo Clin. Proc.,
October 1, 2009;
84(10):
876 - 892.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Gavira, E. Nasarre, G. Abizanda, M. Perez-Ilzarbe, A. de Martino-Rodriguez, J. A. Garcia de Jalon, M. Mazo, A. Macias, I. Garcia-Bolao, B. Pelacho, et al.
Repeated implantation of skeletal myoblast in a swine model of chronic myocardial infarction
Eur. Heart J.,
August 22, 2009;
(2009)
ehp342v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. McKitrick
The arrythmogenic potential of post-myocardial infarction cytokine treatment
Am J Physiol Heart Circ Physiol,
August 1, 2009;
297(2):
H508 - H509.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Krause, K Jaquet, C Schneider, S Haupt, M V Lioznov, K-M Otte, and K-H Kuck
Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study
Heart,
July 15, 2009;
95(14):
1145 - 1152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Agarwal, P. N. Cascade, and F. Pagani
Novel Treatment Options for Chronic Heart Failure: A Radiologist's Perspective
Am. J. Roentgenol.,
July 1, 2009;
193(1):
W14 - W24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Traktuev, D. N. Prater, S. Merfeld-Clauss, A. R. Sanjeevaiah, M. R. Saadatzadeh, M. Murphy, B. H. Johnstone, D. A. Ingram, and K. L. March
Robust Functional Vascular Network Formation In Vivo by Cooperation of Adipose Progenitor and Endothelial Cells
Circ. Res.,
June 19, 2009;
104(12):
1410 - 1420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Shabbir, D. Zisa, G. Suzuki, and T. Lee
Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen
Am J Physiol Heart Circ Physiol,
June 1, 2009;
296(6):
H1888 - H1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Macia and P. A. Boyden
Stem Cell Therapy Is Proarrhythmic
Circulation,
April 7, 2009;
119(13):
1814 - 1823.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Q. Ly and S. Nattel
Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle
Circulation,
April 7, 2009;
119(13):
1824 - 1831.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Nicolini and T. Gherli
Alternatives to transplantation in the surgical therapy for heart failure
Eur. J. Cardiothorac. Surg.,
February 1, 2009;
35(2):
214 - 228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Habeler, S. Pouillot, A. Plancheron, M. Puceat, M. Peschanski, and C. Monville
An in vitro beating heart model for long-term assessment of experimental therapeutics
Cardiovasc Res,
February 1, 2009;
81(2):
253 - 259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Dib, J. Dinsmore, Z. Lababidi, B. White, S. Moravec, A. Campbell, A. Rosenbaum, K. Seyedmadani, W. A. Jaber, C. S. Rizenhour, et al.
One-Year Follow-Up of Feasibility and Safety of the First U.S., Randomized, Controlled Study Using 3-Dimensional Guided Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ischemic Cardiomyopathy (CAuSMIC Study)
J. Am. Coll. Cardiol. Intv.,
January 1, 2009;
2(1):
9 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Gavira, G. Abizanda, M. Perez-Ilzarbe, D. Martinez-Caro, E. Nasarre, A. Perez-Ruiz, and F. Prosper
Skeletal myoblasts for cardiac repair in animal models
Eur. Heart J. Suppl.,
December 1, 2008;
10(suppl_K):
K11 - K15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. V. Huikuri, K. Kervinen, M. Niemela, K. Ylitalo, M. Saily, P. Koistinen, E.-R. Savolainen, H. Ukkonen, M. Pietila, J. K.E. Airaksinen, et al.
Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction
Eur. Heart J.,
November 2, 2008;
29(22):
2723 - 2732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Perez-Ilzarbe, O. Agbulut, B. Pelacho, C. Ciorba, E. S. Jose-Eneriz, M. Desnos, A. A. Hagege, P. Aranda, E. J. Andreu, P. Menasche, et al.
Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium
Eur J Heart Fail,
November 1, 2008;
10(11):
1065 - 1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Farahmand, T. Y.Y. Lai, R. D. Weisel, S. Fazel, T. Yau, P. Menasche, and R.-K. Li
Skeletal Myoblasts Preserve Remote Matrix Architecture and Global Function When Implanted Early or Late After Coronary Ligation Into Infarcted or Remote Myocardium
Circulation,
September 30, 2008;
118(14_suppl_1):
S130 - S137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baldazzi, E. Jorgensen, R. S. Ripa, and J. Kastrup
Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route
Eur. Heart J.,
August 1, 2008;
29(15):
1819 - 1826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tossios, B. Krausgrill, M. Schmidt, T. Fischer, M. Halbach, J. W.U. Fries, S. Fahnenstich, P. Frommolt, I. Heppelmann, A. Schmidt, et al.
Role of balloon occlusion for mononuclear bone marrow cell deposition after intracoronary injection in pigs with reperfused myocardial infarction
Eur. Heart J.,
August 1, 2008;
29(15):
1911 - 1921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Aharinejad, D. Abraham, P. Paulus, K. Zins, M. Hofmann, W. Michlits, M. Gyongyosi, K. Macfelda, T. Lucas, K. Trescher, et al.
Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation
Cardiovasc Res,
August 1, 2008;
79(3):
395 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Atoui, D. Shum-Tim, and R. C.J. Chiu
Myocardial Regenerative Therapy: Immunologic Basis for the Potential "Universal Donor Cells"
Ann. Thorac. Surg.,
July 1, 2008;
86(1):
327 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Pedrotty, R. Y. Klinger, N. Badie, S. Hinds, A. Kardashian, and N. Bursac
Structural coupling of cardiomyocytes and noncardiomyocytes: quantitative comparisons using a novel micropatterned cell pair assay
Am J Physiol Heart Circ Physiol,
July 1, 2008;
295(1):
H390 - H400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Veltman, O. I.I. Soliman, M. L. Geleijnse, W. B. Vletter, P. C. Smits, F. J. ten Cate, L. J. Jordaens, A. H.H.M. Balk, P. W. Serruys, E. Boersma, et al.
Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy
Eur. Heart J.,
June 1, 2008;
29(11):
1386 - 1396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gerosa and C. d'Agostino
Cell therapy in ischemic settings: Fact and fiction.
J. Thorac. Cardiovasc. Surg.,
May 1, 2008;
135(5):
986 - 990.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Orlandi, F. Pagani, D. Avitabile, G. Bonanno, G. Scambia, E. Vigna, F. Grassi, F. Eusebi, S. Fucile, M. Pesce, et al.
Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture
Am J Physiol Heart Circ Physiol,
April 1, 2008;
294(4):
H1541 - H1549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kaczmarczyk
Is the clinical use of adult stem cells a realistic possibility for myocardial regeneration?
Bioscience Horizons,
March 1, 2008;
1(1):
67 - 74.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Traktuev, S. Merfeld-Clauss, J. Li, M. Kolonin, W. Arap, R. Pasqualini, B. H. Johnstone, and K. L. March
A Population of Multipotent CD34-Positive Adipose Stromal Cells Share Pericyte and Mesenchymal Surface Markers, Reside in a Periendothelial Location, and Stabilize Endothelial Networks
Circ. Res.,
January 4, 2008;
102(1):
77 - 85.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-O. Kim, S. Verma, R. D. Weisel, S. Fazel, Z.-Q. Jia, T. Mizuno, and R.-K. Li
Preservation of heart function in diabetic rats by the combined effects of muscle cell implantation and insulin therapy
Eur J Heart Fail,
January 1, 2008;
10(1):
14 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Gallegos and R. M. Bolman III
Stem Cell Induced Regeneration of Myocardium
Card. Surg. Adult,
January 1, 2008;
3(2008):
1657 - 1668.
[Full Text]
|
|
|
|
|
|
|
P. Fotuhi, Y.-H. Song, and E. Alt
Electrophysiological consequence of adipose-derived stem cell transplantation in infarcted porcine myocardium
Europace,
December 1, 2007;
9(12):
1218 - 1221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. K. Hammond
Skeletal Muscle-Derived Stem Cell Transplantation: Angiogenesis Is Required for Improved Left Ventricular Function
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1685 - 1687.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-D. Kan, S.-H. Li, R. D. Weisel, S. Zhang, and R.-K. Li
Recipient Age Determines the Cardiac Functional Improvement Achieved by Skeletal Myoblast Transplantation
J. Am. Coll. Cardiol.,
September 11, 2007;
50(11):
1086 - 1092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Radisic, H Park, S Gerecht, C Cannizzaro, R Langer, and G Vunjak-Novakovic
Biomimetic approach to cardiac tissue engineering
Phil Trans R Soc B,
August 29, 2007;
362(1484):
1357 - 1368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Wu, F. M. Bengel, and S. S. Gambhir
Cardiovascular Molecular Imaging
Radiology,
August 1, 2007;
244(2):
337 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. K. Sim, L. Ye, and H. K. Haider
New Strategy for Cardiac Repair: Genetically Modified Skeletal Myoblasts
Asian Cardiovasc Thorac Ann,
June 1, 2007;
15(3):
183 - 184.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Nussbaum, E. Minami, M. A. Laflamme, J. A. I. Virag, C. B. Ware, A. Masino, V. Muskheli, L. Pabon, H. Reinecke, and C. E. Murry
Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response
FASEB J,
May 1, 2007;
21(7):
1345 - 1357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Prockop and S. D. Olson
Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions
Blood,
April 15, 2007;
109(8):
3147 - 3151.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Katritsis, P. Sotiropoulou, E. Giazitzoglou, E. Karvouni, and M. Papamichail
Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells
Europace,
March 1, 2007;
9(3):
167 - 171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wisel, S. M. Chacko, M. L. Kuppusamy, R. P. Pandian, M. Khan, V. K. Kutala, R. W. Burry, B. Sun, P. Kwiatkowski, and P. Kuppusamy
Labeling of skeletal myoblasts with a novel oxygen-sensing spin probe for noninvasive monitoring of in situ oxygenation and cell therapy in heart
Am J Physiol Heart Circ Physiol,
March 1, 2007;
292(3):
H1254 - H1261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Smith, L. Barile, H. C. Cho, M. K. Leppo, J. M. Hare, E. Messina, A. Giacomello, M. R. Abraham, and E. Marban
Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy Specimens
Circulation,
February 20, 2007;
115(7):
896 - 908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Retuerto, J. T. Beckmann, J. Carbray, G. Patejunas, S. Sarateanu, B. J. Kane, B. Smulevitz, D. D. McPherson, and T. K. Rosengart
Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts
J. Thorac. Cardiovasc. Surg.,
February 1, 2007;
133(2):
478 - 484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Zebedin, M. Mille, M. Speiser, T. Zarrabi, W. Sandtner, B. Latzenhofer, H. Todt, and K. Hilber
C2C12 skeletal muscle cells adopt cardiac-like sodium current properties in a cardiac cell environment
Am J Physiol Heart Circ Physiol,
January 1, 2007;
292(1):
H439 - H450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Bonaros, R. Rauf, D. Wolf, E. Margreiter, A. Tzankov, B. Schlechta, A. Kocher, H. Ott, T. Schachner, S. Hering, et al.
Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure
J. Thorac. Cardiovasc. Surg.,
December 1, 2006;
132(6):
1321 - 1328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kastrup, R. S. Ripa, Y. Wang, and E. Jorgensen
Myocardial regeneration induced by granulocyte-colony-stimulating factor mobilization of stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical stem cell therapy?
Eur. Heart J.,
December 1, 2006;
27(23):
2748 - 2754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Saha, R Zbinden, S R Redwood, and M S Marber
Stem cells to repair the broken heart: much ado about nothing?
Heart,
December 1, 2006;
92(12):
1717 - 1719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lipiecki, N. Durel, and J. Ponsonnaille
Which patients with ischaemic heart disease could benefit from cell replacement therapy?
Eur. Heart J. Suppl.,
December 1, 2006;
8(suppl_H):
H3 - H7.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Menasche, M. Desnos, and A. A. Hagege
Myoblast transplantation during cardiac surgery
Eur. Heart J. Suppl.,
December 1, 2006;
8(suppl_H):
H52 - H56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Siminiak, E. Meliga, O. Jerzykowska, and P. W. Serruys
Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury
Eur. Heart J. Suppl.,
December 1, 2006;
8(suppl_H):
H57 - H64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. W. van Laake, R. Hassink, P. A. Doevendans, and C. Mummery
Heart repair and stem cells
J. Physiol.,
December 1, 2006;
577(2):
467 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zhou, P. D. Acton, and V. A. Ferrari
Imaging Stem Cells Implanted in Infarcted Myocardium
J. Am. Coll. Cardiol.,
November 21, 2006;
48(10):
2094 - 2106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Wu, Y. L. Liu, B. Zhou, and Z. C. Han
Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells
Eur. J. Cardiothorac. Surg.,
November 1, 2006;
30(5):
770 - 781.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Pijnappels, M. J. Schalij, J. van Tuyn, D. L. Ypey, A. A.F. de Vries, E. E. van der Wall, A. van der Laarse, and D. E. Atsma
Progressive increase in conduction velocity across human mesenchymal stem cells is mediated by enhanced electrical coupling
Cardiovasc Res,
November 1, 2006;
72(2):
282 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ben-Dor, S. Fuchs, and R. Kornowski
Potential Hazards and Technical Considerations Associated With Myocardial Cell Transplantation Protocols for Ischemic Myocardial Syndrome
J. Am. Coll. Cardiol.,
October 17, 2006;
48(8):
1519 - 1526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kolossov, T. Bostani, W. Roell, M. Breitbach, F. Pillekamp, J. M. Nygren, P. Sasse, O. Rubenchik, J. W. U. Fries, D. Wenzel, et al.
Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium
J. Exp. Med.,
October 2, 2006;
203(10):
2315 - 2327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hata, G. Matsumiya, S. Miyagawa, H. Kondoh, N. Kawaguchi, N. Matsuura, T. Shimizu, T. Okano, H. Matsuda, and Y. Sawa
Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model
J. Thorac. Cardiovasc. Surg.,
October 1, 2006;
132(4):
918 - 924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-L. Ang, L. Takura Shenje, L. Srinivasan, and M. Galinanes
Repair of the damaged heart by bone marrow cells: from experimental evidence to clinical hope.
Ann. Thorac. Surg.,
October 1, 2006;
82(4):
1549 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Biagini, M. Valgimigli, P. C. Smits, D. Poldermans, A. F.L. Schinkel, V. Rizzello, E. E.M. Onderwater-, M. Bountioukos, and P. W. Serruys
Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure
Eur J Heart Fail,
October 1, 2006;
8(6):
641 - 648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Agbulut, M. Mazo, C. Bressolle, M. Gutierrez, K. Azarnoush, L. Sabbah, N. Niederlander, G. Abizanda, E. J. Andreu, B. Pelacho, et al.
Can bone marrow-derived multipotent adult progenitor cells regenerate infarcted myocardium?
Cardiovasc Res,
October 1, 2006;
72(1):
175 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Christman and R. J. Lee
Biomaterials for the Treatment of Myocardial Infarction
J. Am. Coll. Cardiol.,
September 5, 2006;
48(5):
907 - 913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Caspi and L. Gepstein
Stem cells for myocardial repair
Eur. Heart J. Suppl.,
September 1, 2006;
8(suppl_E):
E43 - E54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. de Boer, M. A.G. van der Heyden, M. B. Rook, R. Wilders, R. Broekstra, B. Kok, M. A. Vos, J. M.T. de Bakker, and T. A.B. van Veen
Pro-arrhythmogenic potential of immature cardiomyocytes is triggered by low coupling and cluster size
Cardiovasc Res,
September 1, 2006;
71(4):
704 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Gavira, M. Perez-Ilzarbe, G. Abizanda, A. Garcia-Rodriguez, J. Orbe, J. A. Paramo, M. Belzunce, G. Rabago, J. Barba, J. Herreros, et al.
A comparison between percutaneous and surgical transplantation of autologous skeletal myoblasts in a swine model of chronic myocardial infarction
Cardiovasc Res,
September 1, 2006;
71(4):
744 - 753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Martens, M. Argenziano, and M. C. Oz
New Technology for Surgical Coronary Revascularization
Circulation,
August 8, 2006;
114(6):
606 - 614.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Boyle, S. P. Schulman, and J. M. Hare
Stem Cell Therapy for Cardiac Repair: Ready for the Next Step
Circulation,
July 25, 2006;
114(4):
339 - 352.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Oettgen
Cardiac Stem Cell Therapy: Need for Optimization of Efficacy and Safety Monitoring
Circulation,
July 25, 2006;
114(4):
353 - 358.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A.B. van Veen, J. M.T. de Bakker, and M. A.G. van der Heyden
Mesenchymal Stem Cells Repair Conduction Block
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
219 - 220.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hendrikx, K. Hensen, C. Clijsters, H. Jongen, R. Koninckx, E. Bijnens, M. Ingels, A. Jacobs, R. Geukens, P. Dendale, et al.
Recovery of Regional but Not Global Contractile Function by the Direct Intramyocardial Autologous Bone Marrow Transplantation: Results From a Randomized Controlled Clinical Trial
Circulation,
July 4, 2006;
114(1_suppl):
I-101 - I-107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Hagege, J.-P. Marolleau, J.-T. Vilquin, A. Alheritiere, S. Peyrard, D. Duboc, E. Abergel, E. Messas, E. Mousseaux, K. Schwartz, et al.
Skeletal Myoblast Transplantation in Ischemic Heart Failure: Long-Term Follow-Up of the First Phase I Cohort of Patients
Circulation,
July 4, 2006;
114(1_suppl):
I-108 - I-113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.C. Guarita-Souza, K.A.T. Carvalho, V. Woitowicz, C. Rebelatto, A. Senegaglia, P. Hansen, N. Miyague, J.C. Francisco, M. Olandoski, J.R. Faria-Neto, et al.
Simultaneous Autologous Transplantation of Cocultured Mesenchymal Stem Cells and Skeletal Myoblasts Improves Ventricular Function in a Murine Model of Chagas Disease
Circulation,
July 4, 2006;
114(1_suppl):
I-120 - I-124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Taheri
Use of autologous adult stem cell for treatment of congestive heart failure
J. Thorac. Cardiovasc. Surg.,
July 1, 2006;
132(1):
214 - 214.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Y. Kresh
Cell replacement therapy: The functional importance of myocardial architecture and intercellular gap-junction distribution
J. Thorac. Cardiovasc. Surg.,
June 1, 2006;
131(6):
1310 - 1313.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Murry, H. Reinecke, and L. M. Pabon
Regeneration Gaps: Observations on Stem Cells and Cardiac Repair
J. Am. Coll. Cardiol.,
May 2, 2006;
47(9):
1777 - 1785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Serruys
Fourth Annual American College of Cardiology International Lecture: A Journey in the Interventional Field
J. Am. Coll. Cardiol.,
May 2, 2006;
47(9):
1754 - 1768.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Chang, L. Tung, R. B. Sekar, C. Y. Chang, J. Cysyk, P. Dong, E. Marban, and M. R. Abraham
Proarrhythmic Potential of Mesenchymal Stem Cell Transplantation Revealed in an In Vitro Coculture Model
Circulation,
April 18, 2006;
113(15):
1832 - 1841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Gavira, J. Herreros, A. Perez, M. J. Garcia-Velloso, J. Barba, F. Martin-Herrero, C. Canizo, A. Martin-Arnau, J. M. Marti-Climent, M. Hernandez, et al.
Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up
J. Thorac. Cardiovasc. Surg.,
April 1, 2006;
131(4):
799 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Furuta, S. Miyoshi, Y. Itabashi, T. Shimizu, S. Kira, K. Hayakawa, N. Nishiyama, K. Tanimoto, Y. Hagiwara, T. Satoh, et al.
Pulsatile Cardiac Tissue Grafts Using a Novel Three-Dimensional Cell Sheet Manipulation Technique Functionally Integrates With the Host Heart, In Vivo
Circ. Res.,
March 17, 2006;
98(5):
705 - 712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. G.P. Welt and D. W. Losordo
Cell Therapy for Acute Myocardial Infarction: Curb Your Enthusiasm?
Circulation,
March 14, 2006;
113(10):
1272 - 1274.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Wu, J. M. Spin, F. Cao, S. Lin, X. Xie, O. Gheysens, I. Y. Chen, A. Y. Sheikh, R. C. Robbins, A. Tsalenko, et al.
Transcriptional profiling of reporter genes used for molecular imaging of embryonic stem cell transplantation
Physiol Genomics,
March 13, 2006;
25(1):
29 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Kolettis
Arrhythmogenesis after cell transplantation post-myocardial infarction. Four burning questions-And some answers
Cardiovasc Res,
February 1, 2006;
69(2):
299 - 301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fernandes, J.-C. Amirault, G. Lande, J.-M. Nguyen, V. Forest, O. Bignolais, G. Lamirault, D. Heudes, J.-L. Orsonneau, M.-F. Heymann, et al.
Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias
Cardiovasc Res,
February 1, 2006;
69(2):
348 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Kuhlmann, P. Kirchhof, R. Klocke, L. Hasib, J. Stypmann, L. Fabritz, M. Stelljes, W. Tian, M. Zwiener, M. Mueller, et al.
G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis
J. Exp. Med.,
January 23, 2006;
203(1):
87 - 97.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods